The National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of local tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table.

jftLVªh löa Mhö ,yö&33004@99 REGD. NO. D. L.-33004/99 vlk/kj.k EXTRAORDINARY Hkkx II—[k.M 3—mi&[k.M (ii) PART II—Section 3—Sub-section (ii) izkf/dkj ls izdkf'kr PUBLISHED BY AUTHORITY la- 944] ubZ fnYyh] cq/okj] ebZ 6] 2015@oS'kk[k 16] 1937 No. 944] NEW DELHI, WEDNESDAY, MAY 6, 2015/VAISAKHA 16, 1937 jlk;u vkSj moZjd ea=kky; ¼vkS"kèk foHkkx½ ¼jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k½ vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1202¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 10, 11, 14 vkSj 16 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] ds vkns'k dk-vk- 3786¼v½ o 3789¼v½] fnukad 20 fnlEcj] 2013, dks tgk¡ rd mldk lEcUèk uhps dh lkj.kh ds fofufeZr iSdksa ls gS] mu ckrksa ds flok; vfèkØkUr djrs gq, ftUgsa ,sls vfèkØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vfèkdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre dher ds #i esa fu;r djrh gSA lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ vfèkdre dher ¼#-½ 1 2 3 4 5 1. fjQSEihflu dSilwy 150 fexzk- 1 dSilwy 1.93 2. fjQSEihflu dSilwy 300 fexzk- 1 dSilwy 3.49 3. fjQSEihflu dSilwy 450 fexzk- 1 dSilwy 5.06 4. fjQSEihflu flji 100 fexzk-@5 fefy 1 fefy 0.35 5. bC;wizksQsu xksfy;ka 200 fexzk- 1 xksyh 0.41 6. bC;wizksQsu xksfy;ka 400 fexzk- 1 xksyh 0.70 2032 GI/2015 (1)2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] uksV % ¼d½ lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vfèkdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vfèkdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vfèkdre [kqnjk dher dks cuk, j[kuk gksxkA ¼[k½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk- vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015- lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr lEcfUèkr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vfèkdre dher ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vfèkdre dher fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ orZeku fofuekZrk flrEcj] 2014 rd ml le; dk ihVhvkj gh izHkkoh gS] o fdlh izdkj of`) ugha djsxk dsoy okf"kZd Fkksd ewY; lwpdkad ds vkèkkj ij of`) dj ldrs gSaA ¼p½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vfèkdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA ¼N½ mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼t½ fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vfèkdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZr;ksa ds iSdksa dh vfèkdre dher fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh vfèkØe.k gks tk;saxsA [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals) (National Pharmaceutical Pricing Authority) ORDER New Delhi, the 6th May, 2015 S.O. 1202(E).—In exercise of the powers, conferred by paragraph 4, 10, 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 3786(E) & 3789(E), dated 20th December, 2013, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of local tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 3 TABLE Sl. Name of the Schedule Formulation Strength Unit Ceiling Price No. (Rs.) (1) (2) (3) (4) (5) 1. Rifampicin Capsule 150mg 1 Capsule 1.93 2. Rifampicin Capsule 300mg 1 Capsule 3.49 3. Rifampicin Capsule 450mg 1 Capsule 5.06 4. Rifampicin Syrup 100mg/5ml 1 ml 0.35 5. Ibuprofen Tablet 200mg 1 Tablet 0.41 6. Ibuprofen Tablet 400mg 1 Tablet 0.70 Note : (a) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013. (b) All the manufacturers are required to follow and ensure to revise their Maximum Retail Price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015 –Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the ceiling price mentioned in the column (5) of the above said table. (d) The ceiling price for a pack of the schedule formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013. (e) The existing manufacturer is not permitted to increase its PTR existing as on September, 2014 except for taking WPI benefit. (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (g) The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulation in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of scheduled formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) The manufacturer not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with the Essential Commodities Act, 1955. (i) Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above table in this notification, the price order(s) if any, issued prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1203¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 10, 11, 14 vkSj 16 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] ds vkns'k dk- vk- 1097¼v½] fnukad 15 Qjojh] 2000, dk- vk- 772¼v½] fnukad 28 ekpZ] 2008 vkSj dk- vk- 3790¼v½] fnukad 20 fnlEcj] 2013, dks tgk¡ rd mldk lEcUèk uhps dh lkj.kh ds fofufeZr iSdksa ls gS] mu ckrksa ds flok; vfèkØkUr djrs gq, ftUgsa ,sls vfèkØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vfèkdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre dher ds :i esa fu;r djrh gSA4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ vfèkdre dher ¼#-½ 1 2 3 4 5 1. ,flVkW;y lsfyflfyd ,sflM xksfy;ka 300 fexzk- 1 xksyh 0.22 2. DyksjksDohu QksLQsV xksfy;ka 150 fexzk- csl 1 xksyh 0.78 3. fjQSEihflu xksyh 50 fexzk- 1 xksyh 0.62 uksV % ¼d½ lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vfèkdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vfèkdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vfèkdre [kqnjk dher dks cuk, j[kuk gksxkA ¼[k½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk- vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015- lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr lEcfUèkr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vfèkdre dher ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vfèkdre dher fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ orZeku fofuekZrk flrEcj] 2013 rd ml le; dk ihVhvkj gh izHkkoh gS] o fdlh izdkj of`) ugha djsxk dsoy okf"kZd Fkksd ewY; lwpdkad ds vkèkkj ij of`) dj ldrs gSaA ¼p½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vfèkdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA ¼N½ mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼t½ fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vfèkdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZr;ksa ds iSdksa dh vfèkdre dher fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh vfèkØe.k gks tk;saxsA [dka- la-@154@22@2015@fo@Qk- la0 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 5 ORDER New Delhi, the 6th May, 2015 S.O. 1203(E).—In exercise of the powers, conferred by paragraph 4, 10, 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 1097(E), dated 15th February, 2000, S.O. 772(E), dated 28th March, 2008 and S.O. 3790(E), dated 20th December, 2013, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of local tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: Sl. Name of the Schedule Formulation Strength Unit Ceiling Price No. (Rs.) (1) (2) (3) (4) (5) 1. Acetyl Salicylic Acid Tablet 300 mg 1 Tablet 0.22 2. Chloroquine Phosphate Tablet 150 mg base 1 Tablet 0.78 3. Rifampicin Tablet 50mg 1 Tablet 0.62 Note : (a) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013. (b) All the manufacturers are required to follow and ensure to revise their Maximum Retail Price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015 –Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the ceiling price mentioned in the column (5) of the above said table. (d) The ceiling price for a pack of the schedule formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013. (e) The existing manufacturer is not permitted to increase its PTR existing as on September, 2013 except for taking WPI benefit. (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (g) The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulation in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of scheduled formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) The manufacturer not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with the Essential Commodities Act, 1955. (i) Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above table in this notification, the price order(s) if any, issued prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1204¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k us vkS"kèk foHkkx }kjk dk-vk- 2360¼v½ fnukad 15.09.2014 ds fLizsuksysDVksu xksyh 25 fexzk- fofufeZfr;ksa ds lEcUèk esa i=k la- 31015/58/2014-ihvkbZ-I fnukad 05.02.2015 ij fn;s x;s vkns'k esa vafdr funsZ'kksa ds dk;kZUo;u gsrq iqufoZyksdu vkns'k ikfjr fd;k x;kA blfy,] mi;qZDr ewY; fuèkkZj.k ds lacaèk esa jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 4, 10, 11, 14 vkSj 16 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky;] jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] ds vkns'k dk- vk- 2360¼v½ fnukad 15 flrEcj] 2014, dk- vk- 3129¼v½ fnukad 10 fnlEcj] 2014 vkSj dk- vk- 619¼v½ fnukad 26 Qjojh] 2015] dks tgk¡ rd mldk lEcUèk uhps dh lkj.kh ds fofufeZr iSdksa ls gS] mu ckrksa ds flok; vfèkØkUr djrs gq, ftUgsa ,sls vfèkØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V vfèkdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre dher ds :i esa fu;r djrh gSA lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ vfèkdre dher ¼#-½ 1 2 3 4 5 1. ,flVkW;y lsfyflfyd ,sflM xksfy;ka 100 fexzk- 1 xksyh 0.17 2 ÝwlkekbM bUtsD'ku 10 fexzk-@fefy 1 fefy 1.58 3. feFkk;yMksik xksfy;ka 250 fexzk- 1 xksyh 2.48 4. izsMuhlksyksu bUtsD'ku 20 fexzk- ¼lksfM;e 1 fefy 4.69 QksLQsV ;k lDlhusV½ 5 osjikfey bUtsD'ku 2.5 fexzk-@fefy 1 fefy 1.12 6 flyoj lYQkfM;kft+u Øhe 1% 1 xzke 0.48 uksV % ¼d½ lHkh ekStwnk fuekZrkvksa dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ksa ds vfèkdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vfèkdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgha Hkh ykxw gks] vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 13(2) ds vuqlkj mldks ekStwnk vfèkdre [kqnjk dher dks cuk, j[kuk gksxkA ¼[k½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk- vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015-lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr lEcfUèkr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vfèkdre dher ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vfèkdre dher fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ orZeku fofuekZrk flrEcj] 2013 rd ml le; dk ihVhvkj gh izHkkoh gS] o fdlh izdkj of`) ugha djsxk dsoy okf"kZd Fkksd ewY; lwpdkad ds vkèkkj ij of`) dj ldrs gSaA ¼p½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vfèkdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 7 ¼N½ mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼t½ fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vfèkdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZr;ksa ds iSdksa dh vfèkdre dher fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh vfèkØe.k gks tk;saxsA [dka- la-@154@22@2015@fo@Qk- la0 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd ORDER New Delhi, the 6th May, 2015 S.O. 1204(E).—In implementation of directions given in line with review order passed by the Department of Pharmaceuticals on 05.02.2015 vide letter no. 31015/58/2014/PI.I in respect of S.O. 2360(E) dated 15.09.2014 for Spironolactone Tablet 25mg. Therefore, in respect of above mentioned price fixation and, in exercise of the powers, conferred by paragraph 4, 10, 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. 2360(E) dated 15th September, 2014, S.O. 3129(E) dated 10th December, 2014 and S.O. 619(E) dated 26th February, 2015, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of local tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Sl. Name of the Schedule Formulation Strength Unit Ceiling Price No. (Rs.) (1) (2) (3) (4) (5) 1. Acetyl Salicylic Acid Tablet 100 mg 1 Tablet 0.17 2. Frusemide Injection 10 mg/ml 1 ml 1.58 3. Methyldopa tablet 250 mg 1 Tablet 2.48 4. Prednisolone Injection 20 mg (as sodium 1 ml 4.69 phosphate or succinate) 5. Verapamil Injection 2.5 mg/ml 1 ml 1.12 6. Silver Sulphadiazine cream 1% 1 gm 0.48 Note : (a) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013. (b) All the manufacturers are required to follow and ensure to revise their Maximum Retail price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015–Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the ceiling price mentioned in the column (5) of the above said table.8 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (d) The ceiling price for a pack of the schedule formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013. (e) The existing manufacturer is not permitted to increase its PTR existing as on September, 2013 except for taking WPI benefit. (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (g) The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulation in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of scheduled formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) The manufacturer not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with the Essential Commodities Act, 1955. (i) Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) of the above table in this notification, the price order(s) if any, issued prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1205¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 6, 11 vkSj 15 }kjk iznRr 'kfDr;k as dk i;z kxs djr s g,q ] rFkk Hkkjr ljdkj d s jlk;u vkjS mojZ d e=a kky;] jk"Vhª; vk"Skèk eYw ; fuèkkjZ .k ikzfèkdj.k ¼ftldk s lfa{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ fFk;ksu QkekZL;wfVdYl fyfeVsM vkSj eSllZ vkbZoh, gsYFkds;j izkbosV fyfeVsM fufeZr vkSj foi.ku fofufnZ"V fofufeZr;ksa Øe'k% esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre [kqnjk ewY; ds :i esa fu;r djrh gSA lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ vfèkdre dher ¼#-½ 1 2 3 4 5 izR;sd fQYe fyfir xksfy;ksa esa 1. lsQiksMksDlhe izksDlsfVy$ lsQiksMksDlhe izksDlsfVy 1 xksyh 12.91 vkW¶yksDlhu xksfy;ka lsQiksMksDlhe-200 fexzk- ds cjkcj vkW¶yksDlhu-200 fexzk- uksV % ¼d½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk- vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015-lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼[k½ fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; fuèkkZfjr djsaxsA¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 9 ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk lEcfUèkr fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA ¼p½ mi;qZDr xSj vfèkdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fuèkkZj.k@la'kksèku ds fy, QkWeZ I ij tek fd;k x;k Fkk vkSj ljdkj }kjk fuèkkZfjr lHkh ykxw oSèkkfud vko';drkvksa dh iwfrZ ds vèkhu izklafxd fofèk;ksa@fu;eksa ds vUrxZr tSls fd dsUnzh;@jkT; ykblfslxa vkfWFkfjVh d s l{ke ikzfèkdkjh }kjk eUs;Qw Ds pfjxa ykblls eta jw h d s rgr lca faèkr fofuferZ fuekrZ k@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼N½ mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa lEcfUèkr fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼t½ fofuekrZ k ;k foi.ku dEiuh] mijkDs r fofufefZr;k as vkjS fofufn"ZV 'krk ±s dk ikyu ugh a djrh g aS rk s o s vko';d oLr,q ¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsaA [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd ORDER New Delhi, the 6th May, 2015 S.O. 1205(E).—In exercise of the powers, conferred by paragraphs 5, 6, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured and marketed by M/s Theon Pharmaceuticals Ltd. and M/s IVA Healthcare Pvt. Ltd. respectively. TABLE Sl. Name of the Schedule Formulation Strength Unit Ceiling Price No. (Rs.) (1) (2) (3) (4) (5) Each film coated tablet contains: 1. Cefpodoxime Proxetil+ Cefpodoxime Proxetil eq. to 1 Tablet 12.91 Ofloxacin tablet Cefpodoxime 200mg Ofloxacin 200mg10 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Note : (a) All the manufacturers are required to follow and ensure to revise their Maximum Retail price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015 –Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015. (b) The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table hereinabove. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in the column (5) of the above said table. (d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013. (e) Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then he shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (f) The above mentioned retail price is applicable only to the individual manufacturers/marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (g) The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its production / import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (i) Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1206¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 6, 11 vkSj 15 }kjk iznRr 'kfDr;k as dk i;z kxs djr s g,q ] rFkk Hkkjr ljdkj d s jlk;u vkjS mojZ d e=a kky;] jk"Vhª; vk"Skèk eYw ; fuèkkjZ .k ikzfèkdj.k ¼ftldk s lfa{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ Lohl xkfuZ;j ykbQlkbal vkSj eSllZ ,QMhlh fyfeVsM fufeZr vkSj foi.ku fofufnZ"V fofufeZr;ksa Øe'k% esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre [kqnjk ewY; ds :i esa fu;r djrh gSA¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 11 lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ vfèkdre dher ¼#-½ 1 2 3 4 5 izR;sd vfyfir ck;ys;MZ xksfy;ksa esa 1. oksxfycksl$ oksxfycksl-0.2 fexzk- 10 xksyh 52.38 esVQksjfeu ,plh,y xksfy;ka esVQksjfeu ,plh,y-500 fexzk- ¼thcksl ,e 0.2½ ¼lLVsUM fjfyt+½ 2. oksxfycksl$ oksxfycksl-0.3 fexzk- 10 xksyh 52.38 esVQksjfeu ,plh,y xksfy;ka esVQksjfeu ,plh,y-500 fexzk- ¼thcksl ,e 0.3½ ¼lLVsUM fjfyt+½ uksV % ¼d½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk- vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015- lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼[k½ fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fuèkkZfjr djsaxsaA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk lEcfUèkr fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA ¼p½ mi;qZDr xSj vfèkdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"kèk ¼ewY; fu;=a k.k½ vkn's k] 2013 d s rgr vucq ) eYw ; fuèkkjZ .k@l'a kkèsku d s fy, QkeW ZI ij tek fd;k x;k Fkk vkjS ljdkj }kjk fuèkkfZjr lHkh ykxw oSèkkfud vko';drkvksa dh iwfrZ ds vèkhu izklafxd fofèk;ksa@fu;eksa ds vUrxZr tSls fd dsUnzh;@jkT; ykblsflax vkWfFkfjVh ds l{ke izkfèkdkjh }kjk esU;wQsDpfjax ykblsl eatwjh ds rgr lacafèkr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSaA ¼N½ mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa lEcfUèkr fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼t½ fofuekrZ k ;k foi.ku dEiuh] mijkDs r fofufefZr;k as vkjS fofufn"ZV 'krk ±s dk ikyu ugh a djrh g aS rk s o s vko';d oLr,q ¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsaA [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd12 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ORDER New Delhi, the 6th May, 2015 S.O. 1206(E).—In exercise of the powers, conferred by paragraphs 5, 6, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured and marketed by M/s Swiss Garnier Lifescience and M/s FDC Ltd. respectively. TABLE Sl. Name of the Schedule Strength Unit Ceiling Price No. Formulation (Rs.) (1) (2) (3) (4) (5) Each uncoated bilayered tablet contains: 1. Voglibose+ Voglibose 0.2mg 10 Tablet 52.38 Metformin HCl Tablet Metformin HCl 500mg (Zibose M 0.2) (Sustained Release) 2. Voglibose+ Voglibose 0.3mg 10 Tablet 52.38 Metformin HCl Tablet Metformin HCl 500mg (Zibose M 0.3) (Sustained Release) Note : (a) All the manufacturers are required to follow and ensure to revise their Maximum Retail price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015 –Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015. (b) The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table hereinabove. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in the column (5) of the above said table. (d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013. (e) Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then he shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (f) The above mentioned retail price is applicable only to the individual manufacturers/marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (g) The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its production / import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 13 (i) Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1207¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 6, 11 vkSj 15 }kjk iznRr 'kfDr;k as dk i;z kxs djr s g,q ] rFkk Hkkjr ljdkj d s jlk;u vkjS mojZ d e=a kky;] jk"Vhª; vk"Skèk eYw ; fuèkkjZ .k ikzfèkdj.k ¼ftldk s lfa{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ es dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ th-,e- ,p- vkWjxsfuDl vkSj eSllZ dsfMyk QkekZL;wfVdYl fyfeVsM fufeZr vkSj foi.ku fofufnZ"V fofufeZr;ksa Øe'k% esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre [kqnjk ewY; ds #i esa fu;r djrh gSA lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ vfèkdre dher ¼#-½ 1 2 3 4 5 izR;sd ok;y esa 1. lsf¶Vfj;sDlksu$ LVªkby lsf¶Vfj;sDlksu lksfM;e izfr ok;y 113.16 VstkscsDV~e bUtsD'ku lsf¶Vfj;sDlksu-1000 fexzk- ds cjkcj LVªkby VstkscsDV~e lksfM;e VstkscsDV~e-125 fexzk- ds cjkcj 2. lsf¶Vfj;sDlksu$ LVªkby lsf¶Vfj;sDlksu lksfM;e izfr ok;y 44.81 VstkscsDV~e bUtsD'ku lsf¶Vfj;sDlksu-250 fexzk- ds cjkcj LVªkby VstkscsDV~e lksfM;e VstkscsDV~e-31.25 fexzk- ds cjkcj uksV % ¼d½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk- vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015- lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼[k½ fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fuèkkZfjr djsaxsaA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSA ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk lEcfUèkr fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA14 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ¼p½ mi;qZDr xSj vfèkdr dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"kèk ¼ewY; fu;=a k.k½ vkn's k] 2013 d s rgr vucq ) eYw ; fuèkkjZ .k@l'a kkèsku d s fy, QkeW ZI ij tek fd;k x;k Fkk vkjS ljdkj }kjk fuèkkfZjr lHkh ykxw oSèkkfud vko';drkvksa dh iwfrZ ds vèkhu izklafxd fofèk;ksa@fu;eksa ds vUrxZr tSls fd dsUnzh;@jkT; ykblsflax vkWfFkfjVh ds l{ke izkfèkdkjh }kjk esU;wQsDpfjax ykblsl eatwjh ds rgr lacafèkr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼N½ mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa lEcfUèkr fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼t½ fofuekrZ k ;k foi.ku dEiuh] mijkDs r fofufefZr;k as vkjS fofufn"ZV 'krk ±s dk ikyu ugh a djrh g aS rk s o s vko';d oLr,q ¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsaA [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd ORDER New Delhi, the 6th May, 2015 S.O. 1207(E).—In exercise of the powers, conferred by paragraphs 5, 6, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured and marketed by M/s G.M.H Organics and M/s Cadila Pharmaceuticals Ltd. respectively. TABLE Sl. Name of the Schedule Strength Unit Ceiling Price No. Formulation (Rs.) (1) (2) (3) (4) (5) Each vial contains: 1. Ceftriaxone + Sterile Ceftriaxone sodium eq. to Each Vial 113.16 Tazobactum Injection Ceftriaxone 1000mg Sterile Tazobactam sodium eq. to Tazobactum 125mg 2. Ceftriaxone + Sterile Ceftriaxone sodium eq. to Each Vial 44.81 Tazobactum Injection Ceftriaxone 250mg Sterile Tazobactam sodium eq. to Tazobactum 31.25mg Note : (a) All the manufacturers are required to follow and ensure to revise their Maximum Retail price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015 –Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015. (b) The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table hereinabove. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in the column (5) of the above said table.¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 15 (d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013. (e) Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then he shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (f) The above mentioned retail price is applicable only to the individual manufacturers/marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (g) The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its production / import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (i) Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1208¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 6, 11 vkSj 15 }kjk iznRr 'kfDr;k as dk i;z kxs djr s g,q ] rFkk Hkkjr ljdkj d s jlk;u vkjS mojZ d e=a kky;] jk"Vhª; vk"Skèk eYw ; fuèkkjZ .k ikzfèkdj.k ¼ftldk s lfa{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ es dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ foaMykl ck;ksVsd fyfeVsM vkSj eSllZ gsxMs ,aM gsxMs QkekZL;wfVdYl fufeZr vkSj foi.ku fofufnZ"V fofufeZr;ksa Øe'k% esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre [kqnjk ewY; ds #i esa fu;r djrh gSA lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ vfèkdre dher ¼#-½ 1 2 3 4 5 izR;sd vfyfir ck;ys;MZ xksyh esa 1. fxfyesizkbM$esVQksjfeu fxfyesizkbM-1 fexzk- 10 xksfy;ka 38.46 ,plh,y xksfy;ka esVQksjfeu ,plh,y-500 fexzk- ¼,p,pXyhe ,e1½ ¼,DLVsUMsM fjfyt+ QkWeZ½ 2. fxfyesizkbM$esVQksjfeu fxfyesizkbM-2 fexzk- 1 xksyh 4.50 ,plh,y xksfy;ka esVQksjfeu ,plh,y-500 fexzk- ¼,p,pXyhe ,e2½ ¼,DLVsUMsM fjfyt+ QkWeZ½16 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] uksV % ¼d½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk- vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015- lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼[k½ fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fuèkkZfjr djsaxsaA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSA ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk lEcfUèkr fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA ¼p½ mi;qZDr xSj vfèkdr dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"kèk ¼ewY; fu;=a k.k½ vkn's k] 2013 d s rgr vucq ) eYw ; fuèkkjZ .k@l'a kkèsku d s fy, QkeW ZI ij tek fd;k x;k Fkk vkjS ljdkj }kjk fuèkkfZjr lHkh ykxw oSèkkfud vko';drkvksa dh iwfrZ ds vèkhu izklafxd fofèk;ksa@fu;eksa ds vUrxZr tSls fd dsUnzh;@jkT; ykblsflax vkWfFkfjVh ds l{ke izkfèkdkjh }kjk esU;wQsDpfjax ykblsl eatwjh ds rgr lacafèkr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼N½ mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa lEcfUèkr fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼t½ fofuekrZ k ;k foi.ku dEiuh] mijkDs r fofufefZr;k as vkjS fofufn"ZV 'krk ±s dk ikyu ugh a djrh g aS rk s o s vko';d oLr,q ¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsaA [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd ORDER New Delhi, the 6th May, 2015 S.O. 1208(E).—In exercise of the powers, conferred by paragraphs 5, 6, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured and marketed by M/s Windlas Biotech Ltd. and M/s Hegde & Hegde Pharmaceuticals respectively.¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 17 TABLE Sl. Name of the Schedule Strength Unit Retail Price No. Formulation (Rs.) (1) (2) (3) (4) (5) Each uncoated bilayered tablet contains: 1. Glimepiride + Glimepiride 1mg 10 Tablet 38.46 Metformin HCl Tablet Metformin HCl 500mg (HHGLIM-M1) (in extended release form) 2. Glimepiride + Glimepiride 2mg 1 Tablet 4.50 Metformin HCl Tablet Metformin HCl 500mg (HHGLIM-M2) (in extended release form) Note : (a) All the manufacturers are required to follow and ensure to revise their Maximum Retail price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015 –Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015. (b) The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table hereinabove. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in the column (5) of the above said table. (d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013. (e) Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then he shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (f) The above mentioned retail price is applicable only to the individual manufacturers/marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (g) The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its production / import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (i) Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director18 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1209¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 6, 11 vkSj 15 }kjk iznRr 'kfDr;k as dk i;z kxs djr s g,q ] rFkk Hkkjr ljdkj d s jlk;u vkjS mojZ d e=a kky;] jk"Vhª; vk"Skèk eYw ; fuèkkjZ .k ikzfèkdj.k ¼ftldk s lfa{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ I;ksj ,aM D;ksj gsYFkds;j izkbosV fyfeVsM vkSj eSllZ Ms~t+ esfMdy LVksj ¼esU;wQSDpfjax½ fyfeVsM fufeZr vkSj foi.ku fofufnZ"V fofufeZr;ksa Øe'k% esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre [kqnjk ewY; ds #i esa fu;r djrh gSA lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ vfèkdre dher ¼#-½ 1 2 3 4 5 izR;sd vfyfir ck;ys;MZ xksyh esa 1. fxfyesizkbM$esVQksjfeu fxfyesizkbM-1 fexzk- 10 xksfy;ka 38.46 ,plh,y xksfy;ka esVQksjfeu ,plh,y-500 fexzk- ¼fxzM 1 ,e½ ¼lLVsUM fjfyt+ QkWeZ esa½ uksV % ¼d½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk- vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015- lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼[k½ fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fuèkkZfjr djsaxsA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk lEcfUèkr fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA ¼p½ mi;qZDr xSj vfèkdr dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fuèkkZj.k@la'kksèku ds fy, QkWeZ I ij tek fd;k x;k Fkk vkSj ljdkj }kjk fuèkkZfjr lHkh ykxw oSèkkfud vko';drkvksa dh iwfrZ ds vèkhu izklafxd fofèk;ksa@fu;eksa ds vUrxZr tSls fd dsUnzh;@jkT; ykblfslxa vkfWFkfjVh d s l{ke ikzfèkdkjh }kjk eUs;Qw Ds pfjxa ykbllas eta jw h d s rgr lca faèkr fofuferZ fuekrZ k@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼N½ mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa lEcfUèkr fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 19 ¼t½ fofuekrZ k ;k foi.ku dEiuh] mijkDs r fofufefZr;k as vkjS fofufn"ZV 'krk ±s dk ikyu ugh a djrh g aS rk s o s vko';d oLr,q ¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsA [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd ORDER New Delhi, the 6th May, 2015 S.O. 1209(E).—In exercise of the powers, conferred by paragraphs 5, 6, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured and marketed by M/s Pure & Cure Healthcare Pvt. Ltd. and M/s Dey’s Medical Stores (Manufacturing) Ltd. respectively. TABLE Sl. Name of the Schedule Strength Unit Retail Price No. Formulation (Rs.) (1) (2) (3) (4) (5) Each uncoated bilayered tablet contains: 1. Glimepiride + Glimepiride 1mg 10’s Tablet 38.46 Metformin HCl Tablet Metformin HCl 500mg (GRID 1M) (in sustained release form) Note : (a) All the manufacturers are required to follow and ensure to revise their Maximum Retail price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015 –Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015. (b) The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table hereinabove. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in the column (5) of the above said table. (d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013. (e) Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then he shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (f) The above mentioned retail price is applicable only to the individual manufacturers/marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (g) The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its production / import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.20 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (h) In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (i) Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1210¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 6, 11 vkSj 15 }kjk iznRr 'kfDr;k as dk i;z kxs djr s g,q ] rFkk Hkkjr ljdkj d s jlk;u vkjS mojZ d e=a kky;] jk"Vhª; vk"Skèk eYw ; fuèkkjZ .k ikzfèkdj.k ¼ftldk s lfa{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ foaMykl ck;ksVsd fyfeVsM vkSj eSllZ ,eD;ksj QkekZL;wfVdYl fyfeVsM fufeZr vkSj foi.ku fofufnZ"V fofufeZr;ksa Øe'k% esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre [kqnjk ewY; ds #i esa fu;r djrh gSA lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ [kqnjk ewY; ¼#-½ 1 2 3 4 5 izR;sd izksyksUt+M fjfyt+ xksyh esa 1. Xyk;fljy VªkbZukbVªsV xksfy;ka MkbZY;wVsM Xyk;fljy VªkbZukbVªsV 1 xksyh 3.69 ¼th3,u 2.6½ Xyk;fljy VªkbZukbVªsV-2.6 fexzk- ds cjkcj 2. Xyk;fljy VªkbZukbVªsV xksfy;ka MkbZY;wVsM Xyk;fljy VªkbZukbVªsV 1 xksyh 4.77 ¼th3,u 6.4½ Xyk;fljy VªkbZukbVªsV-6.4 fexzk- ds cjkcj uksV % ¼d½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk- vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015- lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼[k½ fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fuèkkZfjr djsaxsA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk lEcfUèkr fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 21 ¼p½ mi;qZDr xSj vfèkdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"kèk ¼ewY; fu;=a k.k½ vkn's k] 2013 d s rgr vucq ) eYw ; fuèkkjZ .k@l'a kkèsku d s fy, QkeW ZI ij tek fd;k x;k Fkk vkjS ljdkj }kjk fuèkkfZjr lHkh ykxw oSèkkfud vko';drkvksa dh iwfrZ ds vèkhu izklafxd fofèk;ksa@fu;eksa ds vUrxZr tSls fd dsUnzh;@jkT; ykblsflax vkWfFkfjVh ds l{ke izkfèkdkjh }kjk esU;wQsDpfjax ykblsl eatwjh ds rgr lacafèkr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼N½ mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa lEcfUèkr fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼t½ fofuekrZ k ;k foi.ku dEiuh] mijkDs r fofufefZr;k as vkjS fofufn"ZV 'krk ±s dk ikyu ugh a djrh g aS rk s o s vko';d oLr,q ¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsaA [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd ORDER New Delhi, the 6th May, 2015 S.O. 1210(E).—In exercise of the powers, conferred by paragraphs 5, 6, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured and marketed by M/s Windlas Biotech Ltd. and M/s Emcure Pharmaceuticals Ltd. respectively. TABLE Sl. Name of the Scheduled Strength Unit Ceiling Price No. Formulation (Rs.) (1) (2) (3) (4) (5) Each prolonged release tablet contains: 1. Glyceryl Trinitrate Tablet Diluted Glyceryl Trinitrate 1 Tablet 3.69 (G3N 2.6) eq. to Glyceryl Trinitrate 2.6mg 2. Glyceryl Trinitrate Tablet Diluted Glyceryl Trinitrate 1 Tablet 4.77 (G3N 6.4) eq. to Glyceryl Trinitrate 6.4mg Note : (a) All the manufacturers are required to follow and ensure to revise their Maximum Retail price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015 –Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015. (b) The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table hereinabove. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in the column (5) of the above said table. (d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013.22 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (e) Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then he shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (f) The above mentioned retail price is applicable only to the individual manufacturers/marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (g) The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its production / import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (i) Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1211¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 6, 11 vkSj 15 }kjk iznRr 'kfDr;k as dk i;z kxs djr s g,q ] rFkk Hkkjr ljdkj d s jlk;u vkjS mojZ d e=a kky;] jk"Vhª; vk"Skèk eYw ; fuèkkjZ .k ikzfèkdj.k ¼ftldk s lfa{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ es dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ ,dwEl MªXl ,aM QkekZL;wfVdYl fyfeVsM vkSj eSllZ CY;w ØkWl yscksjsVªht+ fyfeVsM fufeZr vkSj foi.ku fofufnZ"V fofufeZr;ksa Øe'k% esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre [kqnjk ewY; ds #i esa fu;r djrh gSA lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ vfèkdre dher ¼#-½ 1 2 3 4 5 izR;sd fefy ,Ei;wy esa 1. fMDyksQsusd lksfM;e bUtsD'ku fMDyksQsusd lksfM;e-75 fexzk- 1 fefy 14.00 ¼fMDyksVky&,D;w½ uksV % ¼d½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk- vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015- lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼[k½ fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fuèkkZfjr djsaxsaA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSA¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 23 ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk lEcfUèkr fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA ¼p½ mi;qZDr xSj vfèkdr dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"kèk ¼ewY; fu;=a k.k½ vkn's k] 2013 d s rgr vucq ) eYw ; fuèkkjZ .k@l'a kkèsku d s fy, QkeW ZI ij tek fd;k x;k Fkk vkjS ljdkj }kjk fuèkkfZjr lHkh ykxw oSèkkfud vko';drkvksa dh iwfrZ ds vèkhu izklafxd fofèk;ksa@fu;eksa ds vUrxZr tSls fd dsUnzh;@jkT; ykblsflax vkWfFkfjVh ds l{ke izkfèkdkjh }kjk esU;wQsDpfjax ykblsl eatwjh ds rgr lacafèkr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼N½ mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa lEcfUèkr fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼t½ fofuekrZ k ;k foi.ku dEiuh] mijkDs r fofufefZr;k as vkjS fofufn"ZV 'krk ±s dk ikyu ugh a djrh g aS rk s o s vko';d oLr,q ¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsaA [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd ORDER New Delhi, the 6th May, 2015 S.O. 1211(E).—In exercise of the powers, conferred by paragraphs 5, 6, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured and marketed by M/s Akums Drugs & Pharmaceuticals Ltd. and M/s Blue Cross Lab. Ltd. respectively. TABLE Sl. Name of the Schedule Strength Unit Ceiling Price No. Formulation (Rs.) (1) (2) (3) (4) (5) Each ml ampoule contains: 1. Diclofenac Sodium Diclofenac Sodium 75mg 1 ml 14.00 Injection (Diclotal – AQ) Note : (a) All the manufacturers are required to follow and ensure to revise their Maximum Retail price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015 –Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015.24 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (b) The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table hereinabove. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in the column (5) of the above said table. (d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013. (e) Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then he shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (f) The above mentioned retail price is applicable only to the individual manufacturers/marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (g) The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its production / import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (i) Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1212¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 6, 11 vkSj 15 }kjk iznRr 'kfDr;k as dk i;z kxs djr s g,q ] rFkk Hkkjr ljdkj d s jlk;u vkjS mojZ d e=a kky;] jk"Vhª; vk"Skèk eYw ; fuèkkjZ .k ikzfèkdj.k ¼ftldk s lfa{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ es dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ jsfMD;wjk QkekZL;wfVdYl izkbosV fyfeVsM fufeZr vkSj foi.ku fofufnZ"V fofufeZr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre [kqnjk ewY; ds #i esa fu;r djrh gSA lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ vfèkdre dher ¼#-½ 1 2 3 4 5 izR;sd 5 fefy ?kqyus ij ¼iquZxBu½ ds ckn 1. lsfQfDle vkWjy lLisUlu lsfQfDle 1 fefy 2.10 ¼uksokQsDl 100 MªkbZ flji½ ,UgkbMªl lsfQfDle-100 fexzk- ds cjkcj¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 25 uksV % ¼d½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk-vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015- lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼[k½ fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fuèkkZfjr djsaxsaA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSA ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk lEcfUèkr fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA ¼p½ mi;qZDr xSj vfèkdr dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"kèk ¼ewY; fu;=a k.k½ vkn's k] 2013 d s rgr vucq ) eYw ; fuèkkjZ .k@l'a kkèsku d s fy, QkeW ZI ij tek fd;k x;k Fkk vkjS ljdkj }kjk fuèkkfZjr lHkh ykxw oSèkkfud vko';drkvksa dh iwfrZ ds vèkhu izklafxd fofèk;ksa@fu;eksa ds vUrxZr tSls fd dsUnzh;@jkT; ykblsflax vkWfFkfjVh ds l{ke izkfèkdkjh }kjk esU;wQsDpfjax ykblsl eatwjh ds rgr lacafèkr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼N½ mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa lEcfUèkr fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼t½ fofuekrZ k ;k foi.ku dEiuh] mijkDs r fofufefZr;k as vkjS fofufn"ZV 'krk ±s dk ikyu ugh a djrh g aS rk s o s vko';d oLr,q ¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsaA [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd ORDER New Delhi, the 6th May, 2015 S.O. 1212(E).—In exercise of the powers, conferred by paragraphs 5, 6, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured and marketed by M/s Radicura Pharmaceuticals Pvt. Ltd. TABLE Sl. Name of the Schedule Strength Unit Ceiling Price No. Formulation (Rs.) (1) (2) (3) (4) (5) Each 5ml after reconstitution contains: 1. Cefixime Oral Suspension Cefixime eq. to 1 ml 2.10 (Novafex 100 Dry Syrup) Anhydrous Cefixime 100mg26 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Note : (a) All the manufacturers are required to follow and ensure to revise their Maximum Retail price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015 –Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015. (b) The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table hereinabove. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in the column (5) of the above said table. (d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013. (e) Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then he shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (f) The above mentioned retail price is applicable only to the individual manufacturers/marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (g) The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its production / import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (i) Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1213¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 6, 11 vkSj 15 }kjk iznRr 'kfDr;k as dk i;z kxs djr s g,q ] rFkk Hkkjr ljdkj d s jlk;u vkjS mojZ d e=a kky;] jk"Vhª; vk"Skèk eYw ; fuèkkjZ .k ikzfèkdj.k ¼ftldk s lfa{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ es dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ Y;wfiu fyfeVsM fufeZr vkSj foi.ku fofufnZ"V fofufeZr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre [kqnjk ewY; ds #i esa fu;r djrh gSA¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 27 lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ vfèkdre dher ¼#-½ 1 2 3 4 5 izR;sd vfyfir xksyh esa 1. jsehfizy$ jsehfizy-5 fexzk- 1 xksyh 4.29 ,eyksfMfiu xksfy;ka ,eksyksfMfiu ckblk;ysV ¼jsfeLVkj&,5½ ,eksyksfMfiu-5 fexzk- ds cjkcj uksV % ¼d½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk- vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015- lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼[k½ fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fuèkkZfjr djsaxsaA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSA ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk lEcfUèkr fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA ¼p½ mi;qZDr xSj vfèkdr dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"kèk ¼ewY; fu;=a k.k½ vkn's k] 2013 d s rgr vucq ) eYw ; fuèkkjZ .k@l'a kkèsku d s fy, QkeW ZI ij tek fd;k x;k Fkk vkjS ljdkj }kjk fuèkkfZjr lHkh ykxw oSèkkfud vko';drkvksa dh iwfrZ ds vèkhu izklafxd fofèk;ksa@fu;eksa ds vUrxZr tSls fd dsUnzh;@jkT; ykblsflax vkWfFkfjVh ds l{ke izkfèkdkjh }kjk esU;wQsDpfjax ykblsl eatwjh ds rgr lacafèkr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼N½ mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa lEcfUèkr fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼t½ fofuekrZ k ;k foi.ku dEiuh] mijkDs r fofufefZr;k as vkjS fofufn"ZV 'krk ±s dk ikyu ugh a djrh g aS rk s o s vko';d oLr,q ¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kke Lo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsaA [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd28 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ORDER New Delhi, the 6th May, 2015 S.O. 1213(E).—In exercise of the powers, conferred by paragraphs 5, 6, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured and marketed by M/s Lupin Limited. TABLE Sl. Name of the Schedule Strength Unit Ceiling Price No. Formulation (Rs.) (1) (2) (3) (4) (5) Each uncoated tablet contains: 1. Ramipril+ Amlodipine Ramipril 5mg 1 Tablet 4.29 Tablet Amlodipine Besilate eq. to (Ramistar – A5) Amlodipine-5mg Note : (a) All the manufacturers are required to follow and ensure to revise their Maximum Retail price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015 –Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015. (b) The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table hereinabove. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in the column (5) of the above said table. (d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013. (e) Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then he shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (f) The above mentioned retail price is applicable only to the individual manufacturers/marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (g) The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its production / import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (i) Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 29 vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1214¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 6, 11 vkSj 15 }kjk iznRr 'kfDr;k as dk i;z kxs djr s g,q ] rFkk Hkkjr ljdkj d s jlk;u vkjS mojZ d e=a kky;] jk"Vhª; vk"Skèk eYw ; fuèkkjZ .k ikzfèkdj.k ¼ftldk s lfa{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ dsfMyk gsYFkds;j fyfeVsM fufeZr vkSj foi.ku fofufnZ"V fofufeZr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre [kqnjk ewY; ds :i esa fu;r djrh gSA lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ vfèkdre dher ¼#-½ 1 2 3 4 5 izR;sd fQYe fyfir xksfy;ksa esa 1. gk;kslkbu C;wVkbyczksekbM gk;kslkbu C;wVkbyczksekbM-20 fexzk- 1 xksyh 5.63 xkfsy;ka uksV % ¼d½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk- vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015- lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼[k½ fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼5½ es fofufnZ"V [kqnjk ewY; fuèkkZfjr djsaxsA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk lEcfUèkr fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA ¼p½ mi;qZDr xSj vfèkdr dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fuèkkZj.k@la'kksèku ds fy, QkWeZ I ij tek fd;k x;k Fkk vkSj ljdkj }kjk fuèkkZfjr lHkh ykxw oSèkkfud vko';drkvksa dh iwfrZ ds vèkhu izklafxd fofèk;ksa@fu;eksa ds vUrxZr tSls fd dsUnzh;@jkT; ykblfaslxa vkfWFkfjVh d s l{ke ikzfèkdkjh }kjk eUs;Qw Ds pfjxa ykbllas eta jw h d s rgr lca faèkr fofuferZ fuekrZ k@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼N½ mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa lEcfUèkr fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼t½ fofuekrZ k ;k foi.ku dEiuh] mijkDs r fofufefZr;k as vkjS fofufn"ZV 'krk ±s dk ikyu ugh a djrh g aS rk s o s vko';d oLr,q ¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kkeLo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsA [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd30 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ORDER New Delhi, the 6th May, 2015 S.O. 1214(E).—In exercise of the powers, conferred by paragraphs 5, 6, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured and marketed by M/s Cadila Healthcare Ltd. TABLE Sl. Name of the Schedule Strength Unit Ceiling Price No. Formulation (Rs.) (1) (2) (3) (4) (5) Each film coated tablet contains: 1. Hyoscine Butylbromide Hyoscine Butylbromide 20mg 1 Tablet 5.63 Tablet Note : (a) All the manufacturers are required to follow and ensure to revise their Maximum Retail Price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015 –Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015. (b) The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table hereinabove. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in the column (5) of the above said table. (d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013. (e) Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then he shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (f) The above mentioned retail price is applicable only to the individual manufacturers/marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (g) The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its production / import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (i) Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 31 vkns'k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1215¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=kky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013 ds lkFk ifBr vkS"kèk ¼dher fu;a=k.k½ vkns'k] 2013 ds iSjk 5, 6, 11 vkSj 15 }kjk iznRr 'kfDr;k as dk i;z kxs djr s g,q ] rFkk Hkkjr ljdkj d s jlk;u vkjS mojZ d e=a kky;] jk"Vhª; vk"Skèk eYw ; fuèkkjZ .k ikzfèkdj.k ¼ftldk s lfa{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½ esa dh Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk vkSj bZdkbZ ¼;wfuV½ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa eSllZ fliyk fyfeVsM fufeZr vkSj foi.ku fofufnZ"V fofufeZr;ksa esa ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vfèkdre [kqnjk ewY; ds :i esa fu;r djrh gSA lkj.kh Ø-la- vuqlwfpr fofufeZfr dk uke izcyrk bdZ kbZ vfèkdre dher ¼#-½ 1 2 3 4 5 izR;sd ,Dpw;s'ku fMfyoj esa 1. lsyC;wVkeksy lYQsV bUgsyj lsyC;wVkeksy lYQsV-100 ,elhth@Mkst 200 121.08 Mkst+ dkmaVj lfgr ehVj Mkst+ uksV % ¼d½ lHkh fuekZrkvksa ds fy, vko';d gS fd oks ,uihih, }kjk tkjh vkns'k dk- vk- 776¼v½ fnukad 17.3.2015 ds lkFk ifBr Hkkjr ljdkj ds foÙk ea=kky;] ¼jktLo foHkkx½ ds vfèklwpuk la[;k 14/2015 vkSj 15/2015-lsUVªy ,Dlkbt+ fnukad 1 ekpZ] 2015 ds vkèkkj ij vfèkdre ewY; dks ?kVkdj la'kksfèkr djds lqfuf'pr djsaA ¼[k½ fofuZekrk mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼u½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; fuèkkZfjr djsaxsA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vfèkdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; djksa dks tksM+ ldrs gSaA ¼?k½ vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izkoèkkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds vkèkkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fuèkkZfjr djsaA fuekZrk vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 24¼2½ ds rgr QkWeZ V esa ,d ewY; lwph tkjh djsaA ¼M-½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V [kqnjk ewY; ds fy, fofufnZ"V fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk lEcfUèkr fuekZrkvksa }kjk ,d ubZ vkS"kfèk dks ykap djrk gS rks mls igys vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds iSjkxzkQ 2¼u½ ds vuqlkj vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ekè;e ls ,uihih, esa ewY; fuèkkZj.k gsrq vkosnu djuk gksxkA ¼p½ mi;qZDr xSj vfèkdr dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds rgr vuqc) ewY; fuèkkZj.k@la'kksèku ds fy, QkWeZ I ij tek fd;k x;k Fkk vkSj ljdkj }kjk fuèkkZfjr lHkh ykxw oSèkkfud vko';drkvksa dh iwfrZ ds vèkhu izklafxd fofèk;ksa@fu;eksa ds vUrxZr tSls fd dsUnzh;@jkT; ykblfslxa vkfWFkfjVh d s l{ke ikzfèkdkjh }kjk eUs;Qw Ds pfjxa ykblls eta jw h d s rgr lca faèkr fofuferZ fuekrZ k@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼N½ mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcUèk esa lEcfUèkr fuekZrkvksa dks vkS"kèk ¼ewY; fu;a=k.k½ vkns'k] 2013 ds lwph II ds QkWeZ III esa Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcUèk esa vxj fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼t½ fofuekrZ k ;k foi.ku dEiuh] mijkDs r fofufefZr;k as vkjS fofufn"ZV 'krk ±s dk ikyu ugh a djrh g aS rk s o s vko';d oLr,q ¡ vfèkfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izkoèkkuksa ds vèkhu C;kt lfgr vfèkizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA32 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kkeLo:i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gSa] Lor% gh fujLr gks tk;saxsA [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd ORDER New Delhi, the 6th May, 2015 S.O. 1215(E).—In exercise of the powers, conferred by paragraphs 5, 6, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured and marketed by M/s Cipla Ltd. TABLE Sl. Name of the Schedule Strength Unit Ceiling Price No. Formulation (Rs.) (1) (2) (3) (4) (5) Each actuation delivers: 1. Salbutamol Sulphate Salbutamol 200 121.08 Inhaler with dose counter Sulphate-100mcg/dose Metered Dose Note : (a) All the manufacturers are required to follow and ensure to revise their Maximum Retail Price (MRP) (inclusive of excise duty and all taxes) of all formulation packs downward, pursuant to Ministry of Finance (Department of Revenue), vide Notification No. 14/2015 and 15/2015 –Central Excise dated 1st March, 2015 read with the NPPA notification S.O. 776(E) dated 17.3.2015. (b) The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table hereinabove. (c) The manufacturer may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in the column (5) of the above said table. (d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V as per the paragraph 24 (2) of the DPCO, 2013. (e) Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 then he shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013. (f) The above mentioned retail price is applicable only to the individual manufacturers/marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (g) The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its production / import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 33 (i) Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand superseded. [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director 'kqf)&i=k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1216¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k ds vkns'k la0 dk0 vk0 619¼v½] rkjh[k 26 Qjojh] 2015 ¼,eksDlhflfyu+DysO;wfyfud ,sflM lLisU'ku ds fy, ikmMj] 228.5 fexzk-@5 fefy ds vfèkdre ewY; fuèkkZj.k ls lEcfUèkr½, Hkkjr ds jkti=k] vlkèkkj.k esa izdkf'kr lkj.kh ds bZdkbZ dkWye la[;k 4 dh izfof"V 38 dks fuEu izdkj i<+k tk, % ds LFkku ij Þ1 xzkeß i<+k tk, "1 fefyß [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd CORRIGENDUM New Delhi, the 6th May, 2015 S.O. 1216(E).—The National Pharmaceutical Pricing Authority’s Order No. S.O. 619(E) dated the 26th February, 2015 (relating to the ceiling price fixation of Amoxicillin+Clavulinic acid Powder for suspension, 228.5mg/5ml), published in the Gazette of India, Extraordinary, of the Entry at Sl. No. 38 in the Unit column No. (4) of the table, be read as follows : Instead of “1 gm” Read as “1 ml” [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director 'kqf)&i=k ubZ fnYyh] 6 ebZ] 2015 dk-vk- 1217¼v½-—jk"Vªh; vkS"kèk ewY; fuèkkZj.k izkfèkdj.k ds vkns'k la0 dk0 vk0 838¼v½] rkjh[k 25 ekpZ] 2015 ¼LisflfQd ,aVhLusd osue bUtSD'ku iksfyosysUV lksY;w'ku vkSj LisflfQd ,aVhLusd osue yk;ksfQykbTM iksfyosysUV flje] ds vfèkdre ewY; fuèkkZj.k ls lEcfUèkr½, Hkkjr ds jkti=k] vlkèkkj.k esa izdkf'kr lkj.kh ds bZdkbZ dkWye la[;k 4, 5 vkSj 6 dh izfof"V 1 vkSj 2 dks fuEu izdkj i<+k tk, % ds LFkku ij ¼#0½ ¼#0½ "466.79 484.76 566.85 588.67" i<+k tk, ¼#0½ ¼#0½ "46.679 48.476 56.685 58.867" [dka- la-@154@22@2015@fo@Qk- la- 8¼22½@2015@Mhih@,uihih,-&fMoh--II] ujs'k vk;Z] mi&funs'kd34 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] CORRIGENDUM New Delhi, the 6th May, 2015 S.O. 1217(E).—The National Pharmaceutical Pricing Authority’s Order No. S.O. 838(E) dated the 25th March, 2015 (relating to the ceiling price fixation of Specific Antisnake Venom Injection Polyvalent Solution and Specific Antisnake Venom Lyophilyzed Polyvalent Serum), published in the Gazette of India, Extraordinary, of the Entry at Sl. No. 1 and 2 in the Unit column No. (5) and (6) of the table, be read as follows : Instead of (Rs.) (Rs.) “466.79 484.76 566.85 588.67” Read as (Rs.) (Rs.) “46.679 48.476 56.685 58.867” [PN/154/22/2015/F/F. No. 8(22)/2015/D.P./NPPA-Div.-II] NARESH ARYA, Dy. Director Printed by the Manager, Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054.